OptimizeRx Corp (OPRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
OPRX currently has 18.8M outstanding shares. with moderate dilution risk from 8.11M authorized shares representing 43.2% potential dilution. The company has minimally diluted shareholders by 3.01% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 18.8M shares outstanding |
19M | 8.1M |
| Mar 12, 2026 |
10-K filing | 18.6M shares outstanding |
19M | 8.3M |
| Nov 07, 2025 |
10-Q filing | 18.6M shares outstanding |
19M | 8.3M |
| May 13, 2025 |
10-Q filing | 18.5M shares outstanding |
18M | 8.4M |
| Mar 28, 2025 |
S-3 filing: OptimizeRx Corporation files an S-3 to offer and sell up to $75,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units. |
18M | 8.6M |
| Mar 20, 2025 |
10-K filing | 18.3M shares outstanding |
18M | 0 |
| Nov 14, 2024 |
10-Q filing | 18.3M shares outstanding |
18M | 0 |
| Aug 15, 2024 |
10-Q filing | 18.3M shares outstanding |
18M | 0 |
| May 15, 2024 |
10-Q filing | 18.2M shares outstanding |
18M | 0 |
| Apr 15, 2024 |
10-K filing | 17.1M shares outstanding |
17M | 0 |
| Nov 14, 2023 |
10-Q filing | 16.6M shares outstanding |
17M | 0 |
| Oct 25, 2023 |
8-K filing: Medicx's management team purchased 1,444,581 shares of the company's common stock at $7.223 per share for a total of approximately $10.5 million. ($10.5M proceeds) |
17M | 0 |
| Aug 14, 2023 |
10-Q filing | 17.0M shares outstanding |
17M | 0 |
| May 12, 2023 |
10-Q filing | 17.1M shares outstanding |
17M | 0 |
| Mar 10, 2023 |
10-K filing | 17.8M shares outstanding |
18M | 0 |
| Nov 08, 2022 |
10-Q filing | 18.0M shares outstanding |
18M | 0 |
| Aug 09, 2022 |
10-Q filing | 18.1M shares outstanding |
18M | 0 |
| May 09, 2022 |
10-Q filing | 17.9M shares outstanding |
18M | 0 |
| Mar 17, 2022 |
8-K filing: OptimizeRx Corporation will issue up to 240,741 shares of Common Stock to EvinceMed as partial consideration for the acquisition of substantially all of the assets of EvinceMed Corp, with 185,185 being issued at the closing of the acquisition. |
18M | 0 |
| Feb 28, 2022 |
10-K filing | 17.7M shares outstanding |
18M | 0 |
| Nov 09, 2021 |
10-Q filing | 17.6M shares outstanding |
18M | 0 |
| Aug 04, 2021 |
10-Q filing | 17.3M shares outstanding |
17M | 0 |
| May 06, 2021 |
10-Q filing | 16.1M shares outstanding |
16M | 0 |
| Mar 08, 2021 |
10-K filing | 16.8M shares outstanding |
17M | 0 |
| Feb 10, 2021 |
8-K filing: OptimizeRx Corporation completed an underwritten public offering of 1,523,750 shares of its common stock at a price of $49.50 per share, resulting in net proceeds of approximately $70.6 million. ($75.43M proceeds) |
15M | 0 |
| Nov 09, 2020 |
10-Q filing | 14.9M shares outstanding |
15M | 0 |
| Aug 05, 2020 |
10-Q filing | 14.7M shares outstanding |
15M | 0 |
| Jul 10, 2020 |
8-K filing: Douglas Baker, CFO of OptimizeRx Corp., adopted a Rule 10b5-1 stock trading plan to sell up to 41,667 shares of the company's common stock, representing approximately 0.3% of the total outstanding common stock, subject to certain conditions and price thresholds. |
15M | 0 |
| May 06, 2020 |
10-Q filing | 14.6M shares outstanding |
15M | 0 |
| Mar 26, 2020 |
10-K filing | 12.0M shares outstanding |
12M | 0 |